Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ken Yoneda

Critical Care Medicine Sacramento, CA Medical Doctor

NPI 1568423465 CMS profile 298078

2315 Stockton Blvd, University Of California Davis Health System, Sacramento, CA 95817

Open in the dashboard

General payments

$173,450

190 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$371,355 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Ken Yoneda of Sacramento, CA is reported in the CMS Open Payments database as having received $173,450 across 190 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $371,355 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $25,556 25
2024 General $20,357 22
2023 General $17,659 17
2022 General $21,227 41
2021 General $18,574 27
2020 General $15,052 13
2019 General $55,025 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ken Yoneda
  • Critical Care Medicine median
  • Middle half of Critical Care Medicine
  • National median

In program year 2025, general payments to Ken Yoneda were reported at $25,556. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.

Show as a table
Year Ken Yoneda Critical Care Medicine median Middle half National median
2019 $55,025 $149 $51–$535 $163
2020 $15,052 $110 $30–$325 $114
2021 $18,574 $125 $34–$403 $132
2022 $21,227 $157 $49–$582 $149
2023 $17,659 $162 $56–$621 $160
2024 $20,357 $168 $53–$634 $164
2025 $25,556 $189 $59–$844 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $63,341 86 payments
  2. Pfizer Inc. $34,030 10 payments
  3. Intuitive Surgical, Inc. $27,664 43 payments
  4. US Endoscopy $24,500 8 payments
  5. Galvanize Therapeutics, Inc $10,878 13 payments
  6. Noah Medical Corporation $6,046 5 payments
  7. Steris Corporation $4,030 15 payments
  8. AbbVie, Inc. $1,425 2 payments
  9. Pulmonx Corporation $1,347 5 payments
  10. Regeneron Healthcare Solutions, Inc. $130 1 payment
  11. Other $59 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $83,151 28 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $59,200 34 payments
  3. Travel and Lodging $17,525 61 payments
  4. Education $9,020 5 payments
  5. Food and Beverage $4,553 62 payments
Products named General payments · program years 2019–2025
  1. XALKORI $32,471 4 payments
  2. TruFreeze $28,530 23 payments
  3. IMFINZI Oncology $24,717 29 payments
  4. IMFINZI Cardiovascular And Metabolism $18,116 26 payments
  5. ALIYA SYSTEM $10,878 13 payments
  6. IMFINZI Oncology $10,741 10 payments
  7. Da Vinci Surgical System $10,514 35 payments
  8. DA VINCI SP $8,150 5 payments
  9. TAGRISSO $6,489 13 payments
  10. ION $6,000 2 payments
  11. Other $10,143 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$15,827

Medicare's payments for the services billed

Medicare patients

63

Average age 73

Services billed

177

42 women, 21 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Cancer 67%
COPD 49%
Ischemic heart disease 37%
Arthritis 33%
Diabetes 32%
Heart failure 29%
Atrial fibrillation 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TAGRISSO
  • AstraZeneca Pharmaceuticals LP $195
$195 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

190 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record